Pfizer Inc. $PFE Shares Purchased by Lewis Asset Management LLC

Key Points

• Lewis Asset Management LLC increased its stake in Pfizer Inc. by 184.6% during Q2, holding 23,472 shares valued at $569,000 by the end of the reporting period.
• Other institutional investors, including Pacer Advisors Inc. and Amundi, significantly increased their holdings in Pfizer, leading to institutional ownership of 68.36% of the company's stock.
• Pfizer reported $0.78 earnings per share for the last quarter, exceeding analysts' expectations, and declared a quarterly dividend with an annual yield of 7.2%.

Lewis Asset Management LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 184.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,472 shares of the biopharmaceutical company's stock after purchasing an additional 15,224 shares during the quarter. Lewis Asset Management LLC's holdings in Pfizer were worth $569,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Bessemer Group Inc. boosted its stake in shares of Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after purchasing an additional 13,228 shares during the period. Capital Advisors Inc. OK grew its position in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer in the first quarter valued at about $8,283,000. Westbourne Investments Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. lifted its position in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock worth $927,000 after buying an additional 18,200 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock traded up $0.02 during mid-day trading on Monday, hitting $24.05. 67,725,099 shares of the company traded hands, compared to its average volume of 42,502,152. The stock has a market cap of $136.74 billion, a price-to-earnings ratio of 12.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a fifty day moving average price of $24.61 and a 200-day moving average price of $24.18.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.